The real hope for the "sum of the parts" argument is that one or both of the units is more attractive individually and might be taken out for a premium. PDL Biopharma (Nasdaq: PDLI) spun off its drug discovery business, Facet Biotech, which Abbott Labs (NYSE: ABT) eventually purchased.